With FDA approval in sight, why Aerie's keen on global strategy too
With U.S. Food and Drug Administration approval potentially just around the corner, Aerie Pharmaceuticals (Nasdaq: AERI) has its sights set on global strategy as well.
Aerie – which is developing a pipeline of treatments for glaucoma and other eye diseases and is beefing up its research and development team locally – is also well on its way pursuing regulatory approval in both Europe and Japan moving forward.
"The company’s success to date, both clinical ly and financially, is what is allowing…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news
More News: Eyes | Food and Drug Administration (FDA) | Glaucoma | Health Management | Japan Health | Pharmaceuticals